The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment - Takeaways - MDSpire

The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment

  • By

  • Aliki Vasilakou

  • Séverine Loizon

  • Maxime Dubois

  • Paôline Laurent

  • Vanja Sisirak

  • Dorothée Duluc

  • July 2, 2026

  • 0 min

Share

  • 1

    Plasmacytoid dendritic cells (pDCs) produce type I interferons (IFN-I) but often exhibit impaired production in tumor environments.

  • 2

    Tumor-infiltrating pDCs can adopt immunosuppressive properties, indicating a paradox between nucleic acid availability and pDC function.

  • 3

    The tumor microenvironment (TME) may drive pDC dysfunction through factors like cytokines and chemokines that impair their activation.

  • 4

    Impaired IFN-I production by pDCs correlates with poor prognosis in various cancers, suggesting their functional state is crucial.

  • 5

    Understanding the mechanisms that constrain pDC IFN-I responses in tumors is essential for exploring their therapeutic potential.

Original Source(s)

The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment

  • by Aliki Vasilakou, Séverine Loizon, Maxime Dubois, Paôline Laurent, Vanja Sisirak, Dorothée Duluc

  • July 2, 2026

Related Content

RFX5 in cancer: context-dependent molecular functions and emerging translational relevance

Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

  • 1 min